ArticleClinicoEconomics and outcomes research : CEOR2025
Financial Cost of Treating Polytrauma in a Public Tertiary Hospital in the South-Eastern Democratic Republic of Congo: A Case Series Study.
Article in ClinicoEconomics and outcomes research : CEOR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Socio-Economic Impacts of Childhood Sickle Cell Disease on Households in Lubumbashi: An Exploratory Mixed-Methods Study.ClinicoEconomics and outcomes research : CEOR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Polytrauma constitutes a major public health issue that is steadily increasing. In developing countries, including the Democratic Republic of Congo, this phenomenon is exacerbated by a combination of factors, such as inadequate funding mechanisms, the high cost of healthcare services and the low socio-economic level of the populations at risk. This study aims to assess the financial cost of treating polytrauma in a tertiary hospital in the Democratic Republic of the Congo. Patients and Methods: A case series study was conducted at the Jason SENDWE provincial referral general hospital in Lubumbashi, with data collected from 1 January to 31 December 2023. The study was based on the operational definitions of Heinrich and the economic burden of care at the individual level was calculated by dividing the average direct costs by the GDP per capita, PPP of the country. Results: The present study comprised forty patients with polytrauma, with a mean age of 29.73 ± 9.9 years, ranging from 9 to 45 years.Approximately 65% of cases were attributed to road accidents, with a male predominance of 82.5%.The most frequently observed form of vital distress was neurological, accounting for 60% of cases, and le parage chirurgical comme acte chirurgical (28.11%). The overall survival rate was 7.50%, with a mean direct cost per patient of USD 608.77 ± 370.85 (range: USD 139.78 to USD 1826.34). This equates to a financial burden of 93.79 ± 57.13% of GDP per capita, ranging from 21.54 to 281.36% of GDP per capita.The proportion of out-of-pocket payments was 97.5%. The highest proportion of expenditure (42.2%) was attributed to medications, followed by the cost of surgical procedures (23.21%), and then imaging examinations (19.8%). Conversely, the lowest expenditure was observed to be related to resuscitation (1.21%) and laboratory tests (1.83%). It was observed that only polytrauma patients admitted to intensive care and hospitalised for 43 days or more exhibited a higher mean direct cost, with statistically significant differences (at a risk of 5%). Conclusion: Patients with polytrauma are at significant risk of incurring catastrophic health expenditures. The results provide insight into the financial implications of polytrauma, which may inform the organisation of trauma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.